FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hartmann Victor A (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET					2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 02/02/2006 4. If Amendment, Date of Original Filed (Month/Day/Year)								A (Che	5. Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, Strategic & Corp. Devlp. 6. Individual or Joint/Group Filing (Check Applicable				
(Street) CAMBRIDGE MA 02139												- 1 '	Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				2. Transact Date (Month/Day	Execution I		Date,	Code (I	Transaction Disposed Code (Instr.		ties Acquired (A) o d Of (D) (Instr. 3, 4			Securities Beneficia	5. Amount of Securities Beneficially Owned Following		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	Amount (A) or (D)		Price	Transaction (Instr. 3 and				(111501.4)
Common Stock 02/02/				02/02/2	/2006		A		14,501(1)		A	\$0.01	84,501		D			
Common Stock														65	57			shares 401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Code	action (Instr.	Derivative Ex		Expiration	Date Exercisab xpiration Date Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		s Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable		Expiration Date	Title	l c	Amount or Number of Shares	unt (Insti	(Instr. 4)			
Stock Option	\$35.64	02/02/2006		A		108,750		05/02/2006	(2)	02/01/2016		nmon ock	108,750	\$0	258,75	50	D	

Explanation of Responses:

- 1. Stock grant made under 1996 Stock and Option Plan, vesting on 2/2/2010, subject to acceleration upon achievement of certain performance-based milestoned.
- 2. Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/02/2006.

Remarks:

<u>Valerie L. Andrews, Attorney-</u> <u>In-Fact</u> <u>02/06/2006</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.